BCL2L1 and early-onset autosomal dominant Alzheimer disease: Orally delivered soy isoflavones prevented loss of Bcl-xL protein in the rat brain after intraperitoneal injection of amyloid-β peptides (Aβ) indicating the therapeutic potential of soy isoflavones in the treatment of patients with Alzheimer’s disease [108].